Manitoba has bought two million doses of a Canadian-made COVID-19 vaccine on the condition it gets approved for use in Canada and is delivered by the end of the year.
The province has reached a “preliminary agreement” to buy a vaccine under development by Toronto-based Providence Therapeutics, a biotechnology company that has just started to put its product through human clinical trials, Premier Brian Pallister said at a news conference on Thursday.
Pallister called the availability of vaccines from the federal government to Manitoba the province’s “number one limiting factor” in immunizing its population.
“We can’t do our job if the federal government isn’t doing its job,” Pallister said.
Providence’s product is an mRNA vaccine, similar to the Moderna coronavirus shot already being administered across Canada.
The company has purchased a 20,000-square-foot site in Calgary to produce the vaccine, which still must pass through a series of regulatory hoops before it’s approved for use in Canada.
This would be the first time a province directly buys a COVID-19 vaccine. Ottawa assumed responsibility for vaccine purchasing and made deals to buy the Pfizer-BioNTech and Moderna vaccines already in distribution across Canada.
Pallister is among the provincial leaders who criticized the federal government for the move, arguing the provinces were shut out of the decision-making process and left without adequate vaccine supplies.
“The door was slammed in our face repeatedly, and I know other provinces have tried as well,” he said.
Canada lags behind dozens of nations in terms of the proportion of the population that has received doses of a COVID-19 vaccine. The federal Conservative party, among other critics, has blamed the Trudeau government for moving slowly and failing to foster domestic vaccine-production capacity.
“Canada first is in danger of becoming Canada last,” Pallister said.
Canada lacks the capacity to manufacture the millions of doses of coronavirus vaccines needed to immunize people outside of a clinical trial setting. It’s why the federal government struck deals with Pfizer-BioNTech and Moderna — both manufactured abroad — to obtain the vaccines now being rolled out across the country.
Human trials began in January
Providence began the first phase of human trials in January, when it gave shots to 60 adult volunteers at a clinical trial site in Toronto.
Pending regulatory approval, a larger Phase 2 trial with adults over 65, youth under 18 and pregnant women could start in May, Providence CEO Brad Sorenson told CBC News last month.
To date, Manitoba has received 66,090 doses of the Moderna and Pfizer-BioNTech vaccines. Larger quantities of these vaccines are supposed to flow to the province in April.
It is unclear why Manitoba is purchasing the Providence vaccine, which would not be slated to be ready for distribution until later in the year, if it is approved.
As of Wednesday, Manitoba had given 50,554 COVID-19 vaccines to people in the province, Manitoba’s online dashboard says.
That update brought the percentage of Manitobans over 18 who are fully immunized to 1.5 per cent.
View original article here Source